Chemomab Therapeutics Ltd.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 64.63 | -100% | 2.03 | -100% |
| P/S |
|
0 | 33.51 | -100% |
|
|
| P/BV |
|
0.3526 | 4.52 | -92.2% |
|
|
| P/FCF |
|
-0.6156 | 34.27 | -101.8% |
|
|
| Ev/Ebitda |
|
0.1178 | -19.11 | -100.62% |
|
|
| Ev/S |
|
0 | 22.47 | -100% |
|
|
| Ev/FCF |
|
0.1267 | 39.86 | -99.68% |
|
|
| E/P |
|
-1.67 | 0.0134 | -12530.95% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | -14.94 | -100% | 0 | 0% |
| ROE |
|
-142.13 | 6.54 | -2273.89% |
|
|
| ROA |
|
-109.06 | -0.7601 | 14248.38% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
0 | -28.35 | -100% |
|
|
| ROCE |
|
-149.4 | 12.21 | -1323.38% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.0155 | -3.85 | -99.6% | -0.0163 | -5.21% |
| Nеt Debt/Ebitda |
|
0.3544 | -2.93 | -112.09% |
|
|
| Debt/Ratio |
|
0.0177 | 0.17 | -89.59% |
|
|
| Debt/Equity |
|
0.3032 | 0.6659 | -54.47% |
|
|
| Debt/Net Income |
|
-0.0162 | 0.8956 | -101.81% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5431 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.9211 | -100% | ||
| DSI |
|
0 | 0.2368 | -100% |
|
|
| Average dividend growth |
|
0 | 1.26 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4863 | -100% |
|
|
| Average percentage for payments |
|
0 | 64.77 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5431 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | 100.43 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
-5.37 | 49.27 | -110.9% | ||
| Growth impulse Net Income in 5 years |
|
-10.7 | -8.2 | 30.49% | ||
| Growth impulse FCF in 5 years |
|
42.66 | 52.45 | -18.67% | ||
| Growth impulse EPS in 5 years |
|
-85.9 | 5.84 | -1570.89% |
IP Score
3.24/10
